Confidential ODYSSEY Phase 3 Clinical Trial Summary for Praluent (alirocumab)

Confidential ODYSSEY Phase 3 Clinical Trial Summary for Praluent (alirocumab) The passage contains only standard drug trial information, safety warnings, and contact details. It does not mention any influential actors, financial flows, misconduct, or investigative leads. Therefore it offers no actionable investigative value. Key insights: ODYSSEY Phase 3 program includes 14 global trials with >23,500 patients.; Praluent (alirocumab) met primary LDL‑cholesterol reduction endpoints.; Contact numbers and access code appear, but no context linking to wrongdoing.